ReviewSeminars in nuclear medicine2022
Recent Advancements in CT and MR Imaging of Prostate Cancer.
Review in Seminars in nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Development and validation of a nomogram combining PI-RADS v2.1 and clinical indicators for the diagnosis of prostate cancer in patients with PSA ≤ 20 ng/mL.Abdominal radiology (New York) · 2026Article
- Comparison between artificial intelligence-based and manual organ delineations in pretreatment computed tomography scans of prostate cancer patients: a visual grading study.Radiation protection dosimetry · 2026Article
- Insights Into Infections and Inflammation in Prostate Cancer Development and Management: An Overview.BioMed research international · 2026Review
- Recent advances in targeting cyanine dyes: hierarchical targeting mechanisms and theranostic integration for multi-disease precision therapy.Theranostics · 2026Review
- Dual-functional Anti-hPSMAApoptosis : an international journal on programmed cell death · 2025Article
- Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases.European journal of nuclear medicine and molecular imaging · 2025Article
- Bi-Regional Machine Learning Radiomics Based on CT Noninvasively Predicts LOX Expression Level and Overall Survival in Hepatocellular Carcinoma.Cancer medicine · 2025Article
- Comprehensive Analysis of Advancement in Optical Biosensing Techniques for Early Detection of Cancerous Cells.Biosensors · 2025Review
- PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.Journal of cancer research and clinical oncology · 2025Review
- The potential of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography as a main diagnostic tool in prostate cancer staging.Central European journal of urology · 2025Review
- Integration of photomagnetic bimodal imaging to monitor an autogenous exosome loaded platform: unveiling strong targeted retention effects for guiding the photothermal and magnetothermal therapy in a mouse prostate cancer model.Journal of nanobiotechnology · 2024Article
- Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.European journal of nuclear medicine and molecular imaging · 2024Article
- Comparison of Multiparametric MRI, [Cancers · 2023Article
- Article
- New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
CT and MRI are both commonly used in prostate cancer (PCa) management, which includes a large spectrum from screening positive pre-diagnosis phase to metastatic disease. CT and MRI have continually evolved to meet the changing demands for PCa management. For CT, novel techniques such as dual energy CT and photon counting CT show promising results for tissue characterization and quantification. For MRI, the detection, staging, and management of prostate cancer has been significantly improved by the development of multiparametric, biparametric, and whole-body MRI techniques. Additionally, research on ultrasmall superparamagnetic particles of iron oxide contrast-enhanced MRI has revealed promising results for nodal staging of PCa. In this manuscript we aim to outline the current status and recent advancements of CT and MRI in PCa imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.